NeoGenomics, Inc. (NEO)

Market Cap	1.25B -27.7%
Revenue (ttm)	727.33M +10.1%
Net Income	-108.03M
EPS	-0.84
Shares Out	129.81M
PE Ratio	n/a
Forward PE	61.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,805,274
Open	10.18
Previous Close	9.97
Day's Range	9.57 - 10.23
52-Week Range	4.72 - 13.74
Beta	1.58
Analysts	Buy
Price Target	11.14 (+15.44%)
Earnings Date	Feb 17, 2026

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1999
• Employees: 2,500
• Stock Exchange: NASDAQ
• Ticker Symbol: NEO
• Website: https://www.neogenomics.com

Financial Performance

In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for NEO stock is "Buy." The 12-month stock price target is $11.14, which is an increase of 15.44% from the latest price.

Price Target

$11.14

(15.44% upside)

Analyst Consensus: Buy